Safety and preliminary efficacy of three doses of LEO 43204 with ingenol mebutate in patients with actinic keratoses

Trial Profile

Safety and preliminary efficacy of three doses of LEO 43204 with ingenol mebutate in patients with actinic keratoses

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2015

At a glance

  • Drugs Ingenol disoxate (Primary) ; Ingenol mebutate
  • Indications Actinic keratosis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors LEO Pharma
  • Most Recent Events

    • 03 Nov 2015 New trial record
    • 27 Oct 2015 Results published on-line British Journal of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top